NRx Pharmaceuticals, Inc. (NRXP)
NRXP Stock Price Chart
Explore NRx Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze NRXP price movements and trends.
NRXP Company Profile
Discover essential business fundamentals and corporate details for NRx Pharmaceuticals, Inc. (NRXP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Dec 2017
Employees
2.00
Website
https://www.nrxpharma.comCEO
Jonathan C. Javitt
Description
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRXP Financial Timeline
Browse a chronological timeline of NRx Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Aug 2026
EPS estimate is -$0.09, while revenue estimate is $1.75m.
Earnings released on 15 May 2026
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $1.07m , missing expectations by -94.50%.
Earnings released on 23 Mar 2026
EPS came in at $0.19 surpassing the estimated -$0.09 by +311.11%, while revenue for the quarter reached $983.00k , missing expectations by -86.94%.
Earnings released on 14 Nov 2025
EPS came in at -$0.18 falling short of the estimated -$0.11 by -63.64%, while revenue for the quarter reached $242.00k , missing expectations by -96.78%.
Earnings released on 15 May 2025
EPS came in at -$0.34 falling short of the estimated -$0.30 by -13.33%, while revenue for the quarter reached $2.28m .
Earnings released on 14 Mar 2025
EPS came in at -$0.30 falling short of the estimated -$0.20 by -50.00%, while revenue for the quarter reached $4.00k , missing expectations by -99.92%.
Earnings released on 14 Nov 2024
EPS came in at -$0.15 surpassing the estimated -$0.81 by +81.48%.
Earnings released on 14 Aug 2024
EPS came in at -$0.75 surpassing the estimated -$0.81 by +7.41%.
Earnings released on 14 May 2024
EPS came in at -$0.74 falling short of the estimated -$0.55 by -34.55%.
Stock split effective on 2 Apr 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Mar 2024
EPS came in at -$0.50 surpassing the estimated -$0.70 by +28.57%, while revenue for the quarter reached $8.00k .
Earnings released on 13 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$1.10 by +36.36%.
Earnings released on 14 Aug 2023
EPS came in at -$1.20 surpassing the estimated -$1.40 by +14.29%.
Earnings released on 16 May 2023
EPS came in at -$1.30 surpassing the estimated -$1.50 by +13.33%.
Earnings released on 30 Mar 2023
EPS came in at -$1.50 falling short of the estimated -$1.40 by -7.14%.
Earnings released on 14 Nov 2022
EPS came in at -$1.40 matching the estimated -$1.40.
Earnings released on 15 Aug 2022
EPS came in at -$1.50 falling short of the estimated -$1.00 by -50.00%.
Earnings released on 16 May 2022
EPS came in at -$2.50 .
Earnings released on 31 Mar 2022
EPS came in at -$0.90 .
Earnings released on 16 Nov 2021
EPS came in at -$3.90 .
Earnings released on 16 Aug 2021
EPS came in at -$65.10 .
NRXP Stock Performance
Access detailed NRXP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
